Abstract
Background: Autophagy is a physiological pathway characterized by lysosomedependent self-digestion to recycle damaged or superfluous cellular content. Deregulation of autophagy hampers the maintenance of cellular homeostasis and contributes to tumorigenesis. However, during anticancer therapy, autophagy activation contributes to development of resistance. Thus autophagy has been recognized as an important pathway and a therapeutic target in cancer. Nephroblastoma (Wilm's tumor) is a common childhood malignancy. The role of autophagy in nephroblastoma is largely uninvestigated.
Objective: This study is to investigate the change of autophagy level in nephroblastoma, and whether autophagy could be a therapeutic target in anaplastic nephroblastoma.
Method: In clinical samples of childhood nephroblastoma, autophagy activity was evaluated by the expressions of selected autophagy markers as well as the presence of autophagosome ultrastructure. Use of autophagy inhibitors alone and in combination with conventional chemotherapeutics, was studied both in vivo and in vitro.
Results: In nephroblastoma, there was decrease in the Beclin 1 level and the number of autophagosomes, suggesting autophagy inhibition. Furthermore, in two anaplastic nephroblastoma cell lines, G401 and SK-NEP1, autophagy inhibitors further enhanced the efficacy of conventional chemotherapeutics including vincristine and cisplatin. In G401 tumor model established in nude mice, combinational use of chloroquine, an inhibitor of autophagy degradation, further decreased the tumor mass compared with single use of the chemotherapeutics vindesine, although no statistical significance was achieved.
Conclusion: Our results suggest that autophagy deregulation is involved in nephroblastoma, and targeting autophagy can serve as a potential adjuvant strategy for the highly malignant cases.
Keywords: Nephroblastoma, Wilm's tumor, autophagy, Beclin 1, chemotherapy, combinational therapy.
Current Cancer Drug Targets
Title:Autophagy Inhibition in Childhood Nephroblastoma and the Therapeutic Significance
Volume: 18 Issue: 3
Author(s): Lin-Jie Li , Yi-Long Wang, Lin-Qing Yuan, Wei-Zhong Gu, Kun Zhu, Min Yang, Duo Zhou, Yao Lv, Min-Ju Li, Zheng-Yan Zhao, Jin-Hu Wang*Xi Chen*
Affiliation:
- Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang,China
- Key Laboratory of Diagnosis and Treatment of Neonatal Diseases of Zhejiang Province, Zhejiang,China
Keywords: Nephroblastoma, Wilm's tumor, autophagy, Beclin 1, chemotherapy, combinational therapy.
Abstract: Background: Autophagy is a physiological pathway characterized by lysosomedependent self-digestion to recycle damaged or superfluous cellular content. Deregulation of autophagy hampers the maintenance of cellular homeostasis and contributes to tumorigenesis. However, during anticancer therapy, autophagy activation contributes to development of resistance. Thus autophagy has been recognized as an important pathway and a therapeutic target in cancer. Nephroblastoma (Wilm's tumor) is a common childhood malignancy. The role of autophagy in nephroblastoma is largely uninvestigated.
Objective: This study is to investigate the change of autophagy level in nephroblastoma, and whether autophagy could be a therapeutic target in anaplastic nephroblastoma.
Method: In clinical samples of childhood nephroblastoma, autophagy activity was evaluated by the expressions of selected autophagy markers as well as the presence of autophagosome ultrastructure. Use of autophagy inhibitors alone and in combination with conventional chemotherapeutics, was studied both in vivo and in vitro.
Results: In nephroblastoma, there was decrease in the Beclin 1 level and the number of autophagosomes, suggesting autophagy inhibition. Furthermore, in two anaplastic nephroblastoma cell lines, G401 and SK-NEP1, autophagy inhibitors further enhanced the efficacy of conventional chemotherapeutics including vincristine and cisplatin. In G401 tumor model established in nude mice, combinational use of chloroquine, an inhibitor of autophagy degradation, further decreased the tumor mass compared with single use of the chemotherapeutics vindesine, although no statistical significance was achieved.
Conclusion: Our results suggest that autophagy deregulation is involved in nephroblastoma, and targeting autophagy can serve as a potential adjuvant strategy for the highly malignant cases.
Export Options
About this article
Cite this article as:
Li Lin-Jie, Wang Yi-Long , Yuan Lin-Qing, Gu Wei-Zhong, Zhu Kun, Yang Min, Zhou Duo, Lv Yao , Li Min-Ju, Zhao Zheng-Yan , Wang Jin-Hu*, Chen Xi *, Autophagy Inhibition in Childhood Nephroblastoma and the Therapeutic Significance, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170330105433
DOI https://dx.doi.org/10.2174/1568009617666170330105433 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Prevalence of Oral and Systemic Manifestations in Pediatric HIV Cohorts with and without Drug Therapy
Current HIV Research Electrotransfer as a Non Viral Method of Gene Delivery
Current Gene Therapy Distribution and Characteristics of Intrathoracic Lymphadenopathy in TB/HIV Co-Infection
Infectious Disorders - Drug Targets Transmembrane Interactions of HIV-1 Vpu and Tetherin
Current HIV Research Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Synthetic Approaches to Various Class of Topoisomerase II Inhibitors
Mini-Reviews in Organic Chemistry A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents